Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Familial Hypercholesterolemia: Update and Review

Author(s): Oscar Francisco Chacón-Camacho*, Glustein Pozo-Molina, Claudia Fabiola Méndez-Catalá, Julia Reyes-Reali, René Méndez-Cruz and Juan Carlos Zenteno

Volume 22, Issue 2, 2022

Published on: 08 February, 2021

Page: [198 - 211] Pages: 14

DOI: 10.2174/1871530321666210208212148

Price: $65

Abstract

Knowledge of epidemiology, genetic etiopathogenesis, diagnostic criteria, and management of familial hypercholesterolemia have increased in the last two decades. Several population studies have shown that familial hypercholesterolemia is more frequent than previously thought, making this entity the most common metabolic disease with monogenic inheritance in the world. Identification of causal heterozygous pathogenic variants in LDLR, APOB, and PCSK9 genes has increased diagnostic accuracy of classical criteria (extreme hypercholesterolemia, personal / family history of premature coronary artery disease or other cardiovascular diseases). Genetic screening has been recently introduced in many European countries to detect patients with familial hypercholesterolemia, mainly affected pediatric subjects, asymptomatic or those at the beggining of their disease, to increase surveillance and avoid complications such as cardiovascular diseases. Cholesterol- lowering drugs should be started as soon as the diagnosis is made. Various combinations between drugs can be used when the goal is not achieved. New therapies, including small interference ribonucleic acids (siRNA) are being tested in different clinical trials.

Keywords: Dyslipidemia, familial hypercholesterolemia, LDLR, acute myocardial infarction, xanthomas, NGS, mutation.

« Previous Next »
Graphical Abstract

[1]
Berberich, A.J.; Hegele, R.A. The role of genetic testing in dyslipidaemia. Pathology, 2019, 51(2), 184-192.
[http://dx.doi.org/10.1016/j.pathol.2018.10.014] [PMID: 30558903]
[2]
Hopkins, P.N. Genotype-guided diagnosis in familial hypercholesterolemia: population burden and cascade screening. Curr. Opin. Lipidol., 2017, 28(2), 136-143.
[http://dx.doi.org/10.1097/MOL.0000000000000388] [PMID: 28030379]
[3]
Bell, D.A.; Pang, J.; Burrows, S.; Bates, T.R.; van Bockxmeer, F.M.; Hooper, A.J.; O’Leary, P.; Burnett, J.R.; Watts, G.F. Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: an Australian experience. Atherosclerosis, 2015, 239(1), 93-100.
[http://dx.doi.org/10.1016/j.atherosclerosis.2014.12.036] [PMID: 25585028]
[4]
EAS Familial Hypercholesterlaemia studies collaboration; Vellejo-Vaz, A.J.; Akman, A.; Seshasai S.R.K.; Cole, D.; Watts, G.F.; Hovingh, G.K.; Kastelein J.J.P.; Mata, P.; Raal, F.J.; Santos, R.D.; Soran, H.; Freiberger, T.; Abifadel, M.; Aguilar-Salinas, C.A.; Alnouri, F.; Alonso, R.; Al-Rasadi, K.; Banach, M.; Bogsrud, M.P.; Bourbon, M.; Bruckert, E.; Car, J.; Ceska, R.; Corral, P.; Descamps, O.; Dieplinger, H.; Do, C.T.; Durst, R.; Ezhov, M.V.; Fras, Z.; Gaita, D.; Gaspar, I.M.; Genest, J.; Harada-Shiba, G.; Jiang, L; Kayikcioglu, M.; Lam, C.S.P.; Latkovskis, G.; Laufs, U.; Liberopoulos, E.; Lin, J.; Lin, N.; Maher, V.; Majano, N.; Marais, A.D.; März, W.; Mirrakhimov, E.; Miserez A.R.; Mitchenko, O.; Nawawi, H.; Lennart, N.; Nordestgaard, B.G.; Paragh, G.; Petrulioniene, Z.; Pojskic, B.; Reiner, Z.; Sahebkar, A.; Santos, L.E.; Schunkert, H.; Shehab, A.;Slimane, M.N.; Stoll, M.; Su, T.; Susekov, A.; Tilney, M.; Tomlinson, B.; Tselepis, A.D.; Vohnout, B.; Widén, E.; Yamashita, S.; Catapano, A.L.; Ray, K.K. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: rationale and design of the global EAS familial hypercholesterlaemia studies collaboration. Atheroscler. Suppl., 2016, 22, 1-32.
[5]
Andersen, R.; Andersen, L. Examining barriers to cascade screening for familial hypercholesterolemia in the United States. J. Clin. Lipidol., 2016, 10(2), 225-227.
[http://dx.doi.org/10.1016/j.jacl.2015.12.019] [PMID: 27055953]
[6]
Lozano, P.; Henrikson, N.B.; Dunn, J.; Morrison, C.C.; Nguyen, M.; Blasi, P.R.; Anderson, M.L.; Whitlock, E.P. Lipid sreening in childhood and adolescence for detection of familial hypercholesteroleaemia: evidence report and systematic review for the US preventive services task force. JAMA, 2016, 316(6), 645-655.
[http://dx.doi.org/10.1001/jama.2016.6176] [PMID: 27532919]
[7]
Catapano, A.L.; Graham, G.; De Backer, G.; Wiklund, O.; Chapman, J.; Drexel, H.; Hoes, A.W.; Jennings, C.S.; Landmesser, U.; Pedersen, T.R.; Reiner, Z.; Riccardi, G.; Taskinen, M-R.; Tokgozoglu, L.; Verschuren, W.M.M.; Vlachopoulos, C.; Wood, D.A.; Zamorano, J.L. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of atherosclerosis of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis, 2016, 253, 281-344.
[http://dx.doi.org/10.1016/j.atherosclerosis.2016.08.018] [PMID: 27594540]
[8]
Erkelens, D.W.; Sherwood, L.M. Familial hypercholesterolemia, tendinous xanthomas, and Frans Hals. JAMA, 1989, 262(15), 2092.
[http://dx.doi.org/10.1001/jama.262.15.2092c] [PMID: 2677421]
[9]
Dequeker, J.; Muls, E.; Leenders, K. Xanthelasma and lipoma in Leonardo da Vinci’s Mona Lisa. Isr. Med. Assoc. J., 2004, 6(8), 505-506.
[PMID: 15326839]
[10]
Ose, L. The real code of leonardo da vinci. Curr. Cardiol. Rev., 2008, 4(1), 60-62.
[http://dx.doi.org/10.2174/157340308783565401] [PMID: 19924278]
[11]
Fagge, C.H. Xanthomatous diseases of the skin. Trans. Pathol. Soc., 1873, 24, 242-250.
[12]
Muller, C. Xanthoma hypercholesterolaemia, angina pectoris. Acta Med. Scand., 1938, 89, 75-84.
[13]
Wilkinson, C.F., Jr; Hand, E.A.; Fliegelman, M.T. Essential familial hypercholesterolemia. Ann. Intern. Med., 1948, 29(4), 671-686.
[http://dx.doi.org/10.7326/0003-4819-29-4-671] [PMID: 18890269]
[14]
Khachadurian, A.K. The inheritance of essential familial hypercholesterolaemia. Am. J. Med., 1964, 37, 402-407.
[http://dx.doi.org/10.1016/0002-9343(64)90196-2] [PMID: 14209286]
[15]
Goldstein, J.L.; Brown, M.S. Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. Proc. Natl. Acad. Sci. USA, 1973, 70(10), 2804-2808.
[http://dx.doi.org/10.1073/pnas.70.10.2804] [PMID: 4355366]
[16]
Brown, M.S.; Goldstein, J.L. Expression of the familial hypercholesterolemia gene in heterozygotes: mechanism for a dominant disorder in man. Science, 1974, 185(4145), 61-63.
[http://dx.doi.org/10.1126/science.185.4145.61] [PMID: 4366052]
[17]
Endo, A.; Kuroda, M.; Tsujita, Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J. Antibiot. (Tokyo), 1976, 29(12), 1346-1348.
[http://dx.doi.org/10.7164/antibiotics.29.1346] [PMID: 1010803]
[18]
Kastelein, J.J.; Ginsberg, H.N.; Langslet, G.; Hovingh, G.H.; Ceska, R.; Dufour, R.; Blom, R.; Civeira, F.; Krempf, M.; Lorenzato, C.; Zhao, J.; Pordy, R. Baccara,-Dinet, M.T; Gipe, D.A.; Geiger, M.J., Farnier, M. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolemia. Eur. Heart J., 2015, 36(43), 2996-3003.
[PMID: 26330422]
[19]
Sabatine, M.S.; Giugliano, R.P.; Keech, A.C.; Honarpour, N.; Wiviott, S.D.; Murphy, S.A.; Kuder, J.F.; Wang, H.; Liu, T.; Wasserman, S.M.; Sever, P.S.; Pedersen, T.R. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med., 2017, 376(18), 1713-1722.
[http://dx.doi.org/10.1056/NEJMoa1615664] [PMID: 28304224]
[20]
Golstein, J.L.; Hobbs, H.H.; Brown, M.S. Familial Hypercholesterolemia.The metabolic and molecular bases of inherited disease; Scriver, C.R.; Beaudet, A.; Valle, D.; Sly, W.S., Eds.; Mc Graw Hill: New York, 2001, Vol. II, pp. 2863-2913.
[21]
Benn, M.; Watts, G.F.; Tybjaerg-Hansen, A.; Nordestgaard, B.G. Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J. Clin. Endocrinol. Metab., 2012, 97(11), 3956-3964.
[http://dx.doi.org/10.1210/jc.2012-1563] [PMID: 22893714]
[22]
Shi, Z.; Yuan, B.; Zhao, D.; Taylor, A.W.; Lin, J.; Watts, G.F. Familial hypercholesterolemia in China: prevalence and evidence of underdetection and undertreatment in a community population. Int. J. Cardiol., 2014, 174(3), 834-836.
[http://dx.doi.org/10.1016/j.ijcard.2014.04.165] [PMID: 24801084]
[23]
Watts, G.F.; Shaw, J.E.; Pang, J.; Magliano, D.J.; Jennings, G.L.R.; Carrington, M.J. Prevalence and treatment of familial hypercholesterolaemia in Australian communities. Int. J. Cardiol., 2015, 185, 69-71.
[http://dx.doi.org/10.1016/j.ijcard.2015.03.027] [PMID: 25791093]
[24]
Sjouke, B.; Kusters, D.M.; Kindt, I.; Besseling, J.; Defesche, J.C.; Sijbrands, E.J.; Roeters van Lennep, J.E.; Stalenhoef, A.F.; Wiegman, A.; de Graaf, J.; Fouchier, S.W.; Kastelein, J.J.; Hovingh, G.K. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur. Heart J., 2015, 36(9), 560-565.
[http://dx.doi.org/10.1093/eurheartj/ehu058] [PMID: 24585268]
[25]
Benn, M.; Watts, G.F.; Tybjærg-Hansen, A.; Nordestgaard, B.G. Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur. Heart J., 2016, 37(17), 1384-1394.
[http://dx.doi.org/10.1093/eurheartj/ehw028] [PMID: 26908947]
[26]
Nordestgaard, B.G.; Chapman, M.J.; Humphries, S.E.; Ginsberg, H.N.; Masana, L.; Descamps, O.S.; Wiklund, O.; Hegele, R.A.; Raal, F.J.; Defesche, J.C.; Wiegman, A.; Santos, R.D.; Watts, G.F.; Parhofer, K.G.; Hovingh, G.K.; Kovanen, P.T.; Boileau, C.; Averna, M.; Borén, J.; Bruckert, E.; Catapano, A.L.; Kuivenhoven, J.A.; Pajukanta, P.; Ray, K.; Stalenhoef, A.F.H.; Stroes, E.; Taskinen, M.R.; Tybjærg-Hansen, A. European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur. Heart J., 2013, 34(45), 3478-90a.
[http://dx.doi.org/10.1093/eurheartj/eht273] [PMID: 23956253]
[27]
Miller, P.E.; Martin, S.S.; Toth, P.P.; Santos, R.D.; Blaha, M.J.; Nasir, K.; Virani, S.S.; Post, W.S.; Blumenthal, R.S.; Jones, S.R. Screening and advanced lipid phenotyping in familial hypercholesterolemia: The Very Large Database of Lipids Study-17 (VLDL-17). J. Clin. Lipidol., 2015, 9(5), 676-683.
[http://dx.doi.org/10.1016/j.jacl.2015.06.015] [PMID: 26350814]
[28]
Muntoni, S.; Pisciotta, L.; Muntoni, S.; Bertolini, S. Pharmacological treatment of a Sardinian patient affected by Autosomal Recessive Hypercholesterolemia (ARH). J. Clin. Lipidol., 2015, 9(1), 103-106.
[http://dx.doi.org/10.1016/j.jacl.2014.08.009] [PMID: 25670367]
[29]
Akioyamen, L.E.; Genest, J.; Shan, S.D.; Reel, R.L.; Albaum, J.M.; Chu, A.; Tu, J.V. Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. BMJ Open, 2017, 7(9), e016461.
[http://dx.doi.org/10.1136/bmjopen-2017-016461] [PMID: 28864697]
[30]
De Backer, G.; Besseling, J.; Chapman, J.; Hoving, G.K.; Kastelein, J.J.P.; Kotseva, K.; Ray, K.; Reiner, Z.; Wood, D.; De Bacquer, D. EUROASPIRE Investigators. Prevalence and management of familial hypercholesterolaemia in coronary patients an analysis of EUROASPIRE IV, a study of the European Society od Cardiology. Atherosclerosis, 2015, 241(1), 169-175.
[http://dx.doi.org/10.1016/j.atherosclerosis.2015.04.809] [PMID: 25997074]
[31]
Nordestgaard, B.G.; Benn, M. Genetic testing for familial hypercholesterolaemia is essential in individuals with high LDL cholesterol: who does it in the world? Eur. Heart J., 2017, 38(20), 1580-1583.
[http://dx.doi.org/10.1093/eurheartj/ehx136] [PMID: 28419271]
[32]
Hegele, R.A. Plasma lipoproteins: genetic influences and clinical implications. Nat. Rev. Genet., 2009, 10(2), 109-121.
[http://dx.doi.org/10.1038/nrg2481] [PMID: 19139765]
[33]
Goldstein, J.L.; Brown, M.S. The LDL receptor. Arterioscler. Thromb. Vasc. Biol., 2009, 29(4), 431-438.
[http://dx.doi.org/10.1161/ATVBAHA.108.179564] [PMID: 19299327]
[34]
Brown, M.S.; Goldstein, J.L. A receptor-mediated pathway for cholesterol homeostasis. Science, 1986, 232(4746), 34-47.
[http://dx.doi.org/10.1126/science.3513311] [PMID: 3513311]
[35]
Cenarro, A.; Etxebarria, A.; de Castro-Orós, I.; Stef, M.; Bea, A.M.; Palacios, L.; Mateo-Gallego, R.; Benito-Vicente, A.; Ostolaza, H.; Tejedor, T.; Martín, C.; Civeira, F. The p. Leu167del mutation in APOE gene causes autosomal dominant hypercholesterolemia by down-regulation of LDL receptor expression in hepatocytes. J. Clin. Endocrinol. Metab., 2016, 101(5), 2113-2121.
[http://dx.doi.org/10.1210/jc.2015-3874] [PMID: 27014949]
[36]
Fouchier, S.W.; Dallinga-Thie, G.M.; Meijers, J.C.; Zelcer, N.; Kastelein, J.J.; Defesche, J.C.; Hovingh, G.K. Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia. Circ. Res., 2014, 115(6), 552-555.
[http://dx.doi.org/10.1161/CIRCRESAHA.115.304660] [PMID: 25035151]
[37]
Reiner, Ž.; Guardamagna, O.; Nair, D.; Soran, H.; Hovingh, K.; Bertolini, S.; Jones, S.; Ćorić, M.; Calandra, S.; Hamilton, J.; Eagleton, T.; Ros, E.; Ros, E. Lysosomal acid lipase deficiency--an under-recognized cause of dyslipidaemia and liver dysfunction. Atherosclerosis, 2014, 235(1), 21-30.
[http://dx.doi.org/10.1016/j.atherosclerosis.2014.04.003] [PMID: 24792990]
[38]
Rios, J.; Stein, E.; Shendure, J.; Hobbs, H.H.; Cohen, J.C. Identification by whole-genome resequencing of gene defect responsible for severe hypercholesterolemia. Hum. Mol. Genet., 2010, 19(22), 4313-4318.
[http://dx.doi.org/10.1093/hmg/ddq352] [PMID: 20719861]
[39]
Liyanage, K.E.; Burnett, J.R.; Hooper, A.J.; van Bockxmeer, F.M. Familial hypercholesterolemia: epidemiology, Neolithic origins and modern geographic distribution. Crit. Rev. Clin. Lab. Sci., 2011, 48(1), 1-18.
[http://dx.doi.org/10.3109/10408363.2011.565585] [PMID: 21657943]
[40]
Hobbs, H.H.; Brown, M.S.; Goldstein, J.L. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum. Mutat., 1992, 1(6), 445-466.
[http://dx.doi.org/10.1002/humu.1380010602] [PMID: 1301956]
[41]
Bourbon, M.; Alves, A.C.; Sijbrands, E.J. Low-density lipoprotein receptor mutational analysis in diagnosis of familial hypercholesterolemia. Curr. Opin. Lipidol., 2017, 28(2), 120-129.
[http://dx.doi.org/10.1097/MOL.0000000000000404] [PMID: 28169869]
[42]
Usifo, E.; Leigh, S.E.A.; Whittall, R.A.; Lench, N.; Taylor, A.; Yeats, C.; Orengo, C.A.; Martin, A.C.R.; Celli, J.; Humphries, S.E. Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment. Ann. Hum. Genet., 2012, 76(5), 387-401.
[http://dx.doi.org/10.1111/j.1469-1809.2012.00724.x] [PMID: 22881376]
[43]
Wang, J.; Ban, M.R.; Hegele, R.A. Multiplex ligation-dependent probe amplification of LDLR enhances molecular diagnosis of familial hypercholesterolemia. J. Lipid Res., 2005, 46(2), 366-372.
[http://dx.doi.org/10.1194/jlr.D400030-JLR200] [PMID: 15576851]
[44]
Santos, R.D.; Maranhao, R.C. What is new in familial hypercholesterolemia? Curr. Opin. Lipidol., 2014, 25(3), 183-188.
[http://dx.doi.org/10.1097/MOL.0000000000000073] [PMID: 24699416]
[45]
Andersen, L.H.; Miserez, A.R.; Ahmad, Z.; Andersen, R.L. Familial defective apolipoprotein B-100: A review. J. Clin. Lipidol., 2016, 10(6), 1297-1302.
[http://dx.doi.org/10.1016/j.jacl.2016.09.009] [PMID: 27919345]
[46]
Chen, S.H.; Yang, C.Y.; Chen, P.F.; Setzer, D.; Tanimura, M.; Li, W.H.; Gotto, A.M., Jr; Chan, L. The complete cDNA and amino acid sequence of human apolipoprotein B-100. J. Biol. Chem., 1986, 261(28), 12918-12921.
[http://dx.doi.org/10.1016/S0021-9258(18)69248-8] [PMID: 3759943]
[47]
Myant, N.B.; Forbes, S.A.; Day, I.N.; Gallagher, J. Estimation of the age of the ancestral arginine3500-->glutamine mutation in human apoB-100. Genomics, 1997, 45(1), 78-87.
[http://dx.doi.org/10.1006/geno.1997.4898] [PMID: 9339363]
[48]
Humphries, S.E.; Neely, R.D.; Whittall, R.A.; Troutt, J.S.; Konrad, R.J.; Scartezini, M.; Li, K.W.; Cooper, J.A.; Acharya, J.; Neil, A. Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9. Clin. Chem., 2009, 55(12), 2153-2161.
[http://dx.doi.org/10.1373/clinchem.2009.129759] [PMID: 19797716]
[49]
Abifadel, M.; Varret, M.; Rabès, J-P.; Allard, D.; Ouguerram, K.; Devillers, M.; Cruaud, C.; Benjannet, S.; Wickham, L.; Erlich, D.; Derré, A.; Villéger, L.; Farnier, M.; Beucler, I.; Bruckert, E.; Chambaz, J.; Chanu, B.; Lecerf, J-M.; Luc, G.; Moulin, P.; Weissenbach, J.; Prat, A.; Krempf, M.; Junien, C.; Seidah, N.G.; Boileau, C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet., 2003, 34(2), 154-156.
[http://dx.doi.org/10.1038/ng1161] [PMID: 12730697]
[50]
Hopkins, P.N.; Defesche, J.; Fouchier, S.W.; Bruckert, E.; Luc, G.; Cariou, B.; Sjouke, B.; Leren, T.P.; Harada-Shiba, M.; Mabuchi, H.; Rabès, J-P.; Carrié, A.; van Heyningen, C.; Carreau, V.; Farnier, M.; Teoh, Y.P.; Bourbon, M.; Kawashiri, M-A.; Nohara, A.; Soran, H.; Marais, A.D.; Tada, H.; Abifadel, M.; Boileau, C.; Chanu, B.; Katsuda, S.; Kishimoto, I.; Lambert, G.; Makino, H.; Miyamoto, Y.; Pichelin, M.; Yagi, K.; Yamagishi, M.; Zair, Y.; Mellis, S.; Yancopoulos, G.D.; Stahl, N.; Mendoza, J.; Du, Y.; Hamon, S.; Krempf, M.; Swergold, G.D. Characterization of autosomal dominant hypercholesterolemia caused by PCSK9 gain of mutations and its specific treatment with alirocumab, aPCSK9 monoclonal antibody. Circ Cardiovasc Genet, 2015, 8(6), 823-831.
[http://dx.doi.org/10.1161/CIRCGENETICS.115.001129] [PMID: 26374825]
[51]
Awan, Z.; Choi, H.Y.; Stitziel, N.; Ruel, I.; Bamimore, M.A.; Husa, R.; Gagnon, M-H.; Wang, R-H.L.; Peloso, G.M.; Hegele, R.A.; Seidah, N.G.; Kathiresan, S.; Genest, J. APOE p.Leu167del mutation in familial hypercholesterolemia. Atherosclerosis, 2013, 231(2), 218-222.
[http://dx.doi.org/10.1016/j.atherosclerosis.2013.09.007] [PMID: 24267230]
[52]
Fellin, R.; Arca, M.; Zuliani, G.; Calandra, S.; Bertolini, S. The history of Autosomal Recessive Hypercholesterolemia (ARH). From clinical observations to gene identification. Gene, 2015, 555(1), 23-32.
[http://dx.doi.org/10.1016/j.gene.2014.09.020] [PMID: 25225128]
[53]
Fouchier, S.W.; Defesche, J.C. Lysosomal acid lipase A and the hypercholesterolaemic phenotype. Curr. Opin. Lipidol., 2013, 24(4), 332-338.
[http://dx.doi.org/10.1097/MOL.0b013e328361f6c6] [PMID: 23652569]
[54]
Patel, S.B. Recent advances in understanding the STSL locus and ABCG5/ABCG8 biology. Curr. Opin. Lipidol., 2014, 25(3), 169-175.
[http://dx.doi.org/10.1097/MOL.0000000000000071] [PMID: 24811295]
[55]
Umans-Eckenhausen, M.A.; Defesche, J.C.; Sijbrands, E.J.; Scheerder, R.L.; Kastelein, J.J. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet, 2001, 357(9251), 165-168.
[http://dx.doi.org/10.1016/S0140-6736(00)03587-X] [PMID: 11213091]
[56]
Goldberg, A.C.; Hopkins, P.N.; Toth, P.P.; Ballantyne, C.M.; Rader, D.J.; Robinson, J.G.; Daniels, S.R.; Gidding, S.S.; de Ferranti, S.D.; Ito, M.K.; McGowan, M.P.; Moriarty, P.M.; Cromwell, W.C.; Ross, J.L.; Ziajka, P.E. National Lipid Association Expert Panel on Familial Hypercholesterolemia. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Clin. Lipidol., 2011, 5(3)(Suppl.), 133-140.
[http://dx.doi.org/10.1016/j.jacl.2011.03.001] [PMID: 21600517]
[57]
Wierzbicki, A.S.; Humphries, S.E.; Minhas, R. Guideline Development Group. Familial hypercholesterolaemia: summary of NICE guidance. BMJ, 2008, 337, a1095.
[http://dx.doi.org/10.1136/bmj.a1095] [PMID: 18753174]
[58]
Familial hypercholesterolaemia-Report of a second WHO consultation, Geneva. https://apps.who.int/iris/handle/10665/663462020.
[59]
Identification and management of familial hypercholesterolaemia (FH). https://www.nice.org.uk/guidance/cg71/update/CG71/documents/familial-2020.
[60]
Haralambos, K.; Whatley, S.D.; Edwards, R.; Gingell, R.; Townsend, D.; Ashfield-Watt, P.; Lansberg, P.; Datta, D.B.N.; McDowell, I.F.W. Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales. Atherosclerosis, 2015, 240(1), 190-196.
[http://dx.doi.org/10.1016/j.atherosclerosis.2015.03.003] [PMID: 25797312]
[61]
Wiegman, A.; Gidding, S.S.; Watts, G.F.; Chapman, M.J.; Ginsberg, H.N.; Cuchel, M.; Ose, L.; Averna, M.; Boileau, C.; Borén, J.; Bruckert, E.; Catapano, A.L.; Defesche, J.C.; Descamps, O.S.; Hegele, R.A.; Hovingh, G.K.; Humphries, S.E.; Kovanen, P.T.; Kuivenhoven, J.A.; Masana, L.; Nordestgaard, B.G.; Pajukanta, P.; Parhofer, K.G.; Raal, F.J.; Ray, K.K.; Santos, R.D.; Stalenhoef, A.F.H.; Steinhagen-Thiessen, E.; Stroes, E.S.; Taskinen, M.R.; Tybjærg-Hansen, A.; Wiklund, O. European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur. Heart J., 2015, 36(36), 2425-2437.
[http://dx.doi.org/10.1093/eurheartj/ehv157] [PMID: 26009596]
[62]
Martin, R.; Latten, M.; Hart, P.; Murray, H.; Bailie, D.A.; Crockard, M.; Lamont, J.; Fitzgerald, P.; Graham, C.A. Genetic diagnosis of familial hypercholesterolaemia using a rapid biochip array assay for 40 common LDLR, APOB and PCSK9 mutations. Atherosclerosis, 2016, 254, 8-13.
[http://dx.doi.org/10.1016/j.atherosclerosis.2016.09.061] [PMID: 27680772]
[63]
Graham, C.A.; Latten, M.J.; Hart, P.J. Molecular diagnosis of familial hypercholesterolaemia. Curr. Opin. Lipidol., 2017, 28(4), 313-320.
[http://dx.doi.org/10.1097/MOL.0000000000000430] [PMID: 28463860]
[64]
Maglio, C.; Mancina, R.M.; Motta, B.M.; Stef, M.; Pirazzi, C.; Palacios, L.; Askaryar, N.; Borén, J.; Wiklund, O.; Romeo, S. Genetic diagnosis of familial hypercholesterolaemia by targeted next-generation sequencing. J. Intern. Med., 2014, 276(4), 396-403.
[http://dx.doi.org/10.1111/joim.12263] [PMID: 24785115]
[65]
Katsanis, S.H.; Katsanis, N. Molecular genetic testing and the future of clinical genomics. Nat. Rev. Genet., 2013, 14(6), 415-426.
[http://dx.doi.org/10.1038/nrg3493] [PMID: 23681062]
[66]
Strande, N.T.; Berg, J.S. Defining the clinical value of a genomic diagnosis in the era of next-generation sequencing. Annu. Rev. Genomics Hum. Genet., 2016, 17, 303-332.
[http://dx.doi.org/10.1146/annurev-genom-083115-022348] [PMID: 27362341]
[67]
de Koning, T.J.; Jongbloed, J.D.; Sikkema-Raddatz, B.; Sinke, R.J. Targeted next-generation sequencing panels for monogenetic disorders in clinical diagnostics: the opportunities and challenges. Expert Rev. Mol. Diagn., 2015, 15(1), 61-70.
[http://dx.doi.org/10.1586/14737159.2015.976555] [PMID: 25367078]
[68]
Xuan, J.; Yu, Y.; Qing, T.; Guo, L.; Shi, L. Next-generation sequencing in the clinic: promises and challenges. Cancer Lett., 2013, 340(2), 284-295.
[http://dx.doi.org/10.1016/j.canlet.2012.11.025] [PMID: 23174106]
[69]
Vissers, L.E.; de Ligt, J.; Gilissen, C.; Janssen, I.; Steehouwer, M.; de Vries, P.; van Lier, B.; Arts, P.; Wieskamp, N.; del Rosario, M.; van Bon, B.W.; Hoischen, A.; de Vries, B.B.; Brunner, H.G.; Veltman, J.A. A de novo paradigm for mental retardation. Nat. Genet., 2010, 42(12), 1109-1112.
[http://dx.doi.org/10.1038/ng.712] [PMID: 21076407]
[70]
Gilissen, C.; Hoischen, A.; Brunner, H.G.; Veltman, J.A. Disease gene identification strategies for exome sequencing. Eur. J. Hum. Genet., 2012, 20(5), 490-497.
[http://dx.doi.org/10.1038/ejhg.2011.258] [PMID: 22258526]
[71]
Sure Select Target enrichment system. For Illumina multiplexed sequencing platforms. Protocol. Agilent Technologies. https://www.genomics.agilent.com/article.jsp?pageId=3083
[72]
Illumina products. TruSight one sequencing panels. https://www.illumina.com/products/by-type/clinical-research-products/trusight-one.html 2020.
[73]
Illumina. Cancer genomics research. Targeting known variants for cancer related genes. https://www.illumina.com/areas-of-interest/cancer/research/sequencing-methods/targeted-cancer-seq.html
[74]
Sikkema-Raddatz, B.; Johansson, L.F.; de Boer, E.N.; Almomani, R.; Boven, L.G.; van den Berg, M.P.; van Spaendonck-Zwarts, K.Y.; van Tintelen, J.P.; Sijmons, R.H.; Jongbloed, J.D.; Sinke, R.J. Targeted next-generation sequencing can replace Sanger sequencing in clinical diagnostics. Hum. Mutat., 2013, 34(7), 1035-1042.
[http://dx.doi.org/10.1002/humu.22332] [PMID: 23568810]
[75]
Radovica-Spalvina, I.; Latkovskis, G.; Silamikelis, I.; Fridmanis, D.; Elbere, I.; Ventins, K.; Ozola, G.; Erglis, A.; Klovins, J. Next-generation-sequencing-based identification of familial hypercholesterolemia-related mutations in subjects with increased LDL-C levels in a latvian population. BMC Med. Genet., 2015, 16, 86.
[http://dx.doi.org/10.1186/s12881-015-0230-x] [PMID: 26415676]
[76]
Norsworthy, P.J.; Vandrovcova, J.; Thomas, E.R.A.; Campbell, A.; Kerr Soutar, A.K.; Smith, B.H.; Dominiczak, A.F.; Porteous, D.J.; Morris, A.D. Generation Scotland; Aitman; T.J. Targeted genetic testing for familial hypercholesterolemia using next generation sequencing: a population-based study. BMC Med. Genet., 2014, 15, 70.
[http://dx.doi.org/10.1186/1471-2350-15-70] [PMID: 24956927]
[77]
Pirillo, A.; Garlaschelli, K.; Arca, M.; Averna, M.; Bertolini, S.; Calandra, S.; Tarugi, P.; Catapano, A.L. LIPIGEN Group. Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. Atheroscler. Suppl., 2017, 29, 17-24.
[http://dx.doi.org/10.1016/j.atherosclerosissup.2017.07.002] [PMID: 28965616]
[78]
Futema, M.; Plagnol, V.; Li, K.; Whittall, R.A.; Neil, H.A.W.; Seed, M. Simon Broome Consortium. Whole exome secuencing of familial hypercholesterolemia patients negative for LDLR/APOB/PCSK9 mutations. J. Med. Genet., 2014, 51(8), 537-544.
[http://dx.doi.org/10.1136/jmedgenet-2014-102405] [PMID: 24987033]
[79]
Al-Allaf, F.A.; Athar, M.; Abduljaleel, Z.; Taher, M.M.; Khan, W.; Ba-Hammam, F.A.; Abalkhail, H.; Alashwal, A. Next generation sequencing to identify novel genetic variants causative of autosomal dominant familial hypercholesterolemia associated with increased risk of coronary heart disease. Gene, 2015, 565(1), 76-84.
[http://dx.doi.org/10.1016/j.gene.2015.03.064] [PMID: 25839937]
[80]
Brænne, I.; Kleinecke, M.; Reiz, B.; Graf, E.; Strom, T.; Wieland, T.; Fischer, M.; Kessler, T.; Hengstenberg, C.; Meitinger, T.; Erdmann, J.; Schunkert, H. Systematic analysis of variants related to familial hypercholesterolemia in families with premature myocardial infarction. Eur. J. Hum. Genet., 2016, 24(2), 191-197.
[http://dx.doi.org/10.1038/ejhg.2015.100] [PMID: 26036859]
[81]
Central Intelligence Agency. The World Factbook., 2014.https://www.cia.gov/library/publications/download/download-2014/index.html
[82]
DeGoma, E.M.; Ahmad, Z.S.; O’Bien, E.C.; Kindt, I.; Shrader, P.; Newman, C.B.; Pokharel, Y.; Baum, S.J.; Hemphill, L.C.; Hudgins, L.C.; Ahmed, C.D.; Gidding, S.S.; Duffy, D.; Neal, W.; Wilemon, K.; Roe, M.T.; Rader, D.J.; Ballantyne, C.M.; Linton, M.F.; Duell, P.; Shapiro, M.D.; Moriarty, P.M.; Knowles, J.W. Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States: data from the CASCADE-familial hypercholesterolemia registry. Circ Cardiovasc Genet, 2016, 9(3), 240-249.
[http://dx.doi.org/10.1161/CIRCGENETICS.116.001381] [PMID: 27013694]
[83]
Daniels, S.R.; Gidding, S.S.; de Ferranti, S.D. Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Clin. Lipidol., 2011, 5(3)(Suppl.), S30-S37.
[http://dx.doi.org/10.1016/j.jacl.2011.03.453] [PMID: 21600527]
[84]
Wiegman, A.; Hutten, B.A.; de Groot, E.; Rodenburg, J.; Bakker, H.D.; Büller, H.R.; Sijbrands, E.J.; Kastelein, J.J. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA, 2004, 292(3), 331-337.
[http://dx.doi.org/10.1001/jama.292.3.331] [PMID: 15265847]
[85]
Narverud, I.; Retterstøl, K.; Iversen, P.O.; Halvorsen, B.; Ueland, T.; Ulven, S.M.; Ose, L.; Aukrust, P.; Veierød, M.B.; Holven, K.B. Markers of atherosclerotic development in children with familial hypercholesterolemia: a literature review. Atherosclerosis, 2014, 235(2), 299-309.
[http://dx.doi.org/10.1016/j.atherosclerosis.2014.05.917] [PMID: 24908240]
[86]
Kusters, D.M.; de Beaufort, C.; Widhalm, K.; Guardamagna, O.; Bratina, N.; Ose, L.; Wiegman, A. Paediatric screening for hypercholesterolaemia in Europe. Arch. Dis. Child., 2012, 97(3), 272-276.
[http://dx.doi.org/10.1136/archdischild-2011-300081] [PMID: 21949015]
[87]
McGill, H.C., Jr; McMahan, C.A.; Gidding, S.S. Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. Circulation, 2008, 117(9), 1216-1227.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.107.717033] [PMID: 18316498]
[88]
Public Health Papers 34. Principles and Practice of screening for disease., 1968, https://apps.who.int/iris/bitstream/handle/10665/37650/WHO_PHP_34.pdf?sequence=17
[89]
Kwiterovich, P.O.; Gidding, S.S. Universal screening of cholesterol in children. Clin. Cardiol., 2012, 35(11), 662-664.
[http://dx.doi.org/10.1002/clc.22050] [PMID: 22930527]
[90]
Wald, D.S.; Bestwick, J.P.; Wald, N.J. Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis. BMJ, 2007, 335(7620), 599.
[http://dx.doi.org/10.1136/bmj.39300.616076.55] [PMID: 17855284]
[91]
Leren, T.P.; Finborud, T.H.; Manshaus, T.E.; Ose, L.; Berge, K.E. Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. Community Genet., 2008, 11(1), 26-35.
[PMID: 18196915]
[92]
Datta, B.N.; McDowell, I.F.; Rees, A. Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemia. Curr. Opin. Lipidol., 2010, 21(4), 366-371.
[http://dx.doi.org/10.1097/MOL.0b013e32833c14e2] [PMID: 20613514]
[93]
Genest, J.; Hegele, R.A.; Bergeron, J.; Brophy, J.; Carpentier, A.; Couture, P.; Davignon, J.; Dufour, R.; Frohlich, J.; Gaudet, D.; Gupta, M.; Krisnamoorthy, P.; Mancini, J.; McCrindle, B.; Raggi, P.; Ruel, I.; St-Pierre, J. Canadian Cardiovascular Society position statement on familial hypercholesterolemia. Can. J. Cardiol., 2014, 30(12), 1471-1481.
[http://dx.doi.org/10.1016/j.cjca.2014.09.028] [PMID: 25448461]
[94]
Andermann, A.; Blancquaert, I.; Beauchamp, S.; Déry, V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull. World Health Organ., 2008, 86(4), 317-319.
[http://dx.doi.org/10.2471/BLT.07.050112] [PMID: 18438522]
[95]
Louter, L.; Defesche, J.; Roeters van Lennep, J. Cascade screening for familial hypercholesterolemia: Practical consequences. Atheroscler. Suppl., 2017, 30, 77-85.
[http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.019] [PMID: 29096865]
[96]
Ademi, Z.; Watts, G.F.; Pang, J.; Sijbrands, E.J.E.; van Bockxmeer, F.M.; O’Leary, P.; Geelhoed, E.; Liew, D. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. J. Clin. Lipidol., 2014, 8(4), 390-400.
[http://dx.doi.org/10.1016/j.jacl.2014.05.008] [PMID: 25110220]
[97]
Chen, C.X.; Hay, J.W. Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States. Int. J. Cardiol., 2015, 181, 417-424.
[http://dx.doi.org/10.1016/j.ijcard.2014.12.070] [PMID: 25569270]
[98]
Alonso, R.; Perez de Isla, L.; Muñiz-Grijalvo, O.; Mata, P. Barriers to early diagnosis and treatment of familial hypercholesterolemia: current perspectives on improving patient care. Vasc. Health Risk Manag., 2020, 16, 11-25.
[http://dx.doi.org/10.2147/VHRM.S192401] [PMID: 32021224]
[99]
Vallejo-Vaz, A.J.; Akram, A.; Kondapally Seshasai, S.R.; Cole, D.; Watts, G.F.; Hovingh, G.K.; Kastelein, J.J.; Mata, P.; Raal, F.J.; Santos, R.D.; Soran, H.; Freiberger, T.; Abifadel, M.; Aguilar-Salinas, C.A.; Alnouri, F.; Alonso, R.; Al-Rasadi, K.; Banach, M.; Bogsrud, M.P.; Bourbon, M.; Bruckert, E.; Car, J.; Ceska, R.; Corral, P.; Descamps, O.; Dieplinger, H.; Do, C.T.; Durst, R.; Ezhov, M.V.; Fras, Z.; Gaita, D.; Gaspar, I.M.; Genest, J.; Harada-Shiba, M.; Jiang, L.; Kayikcioglu, M.; Lam, C.S.; Latkovskis, G.; Laufs, U.; Liberopoulos, E.; Lin, J.; Lin, N.; Maher, V.; Majano, N.; Marais, A.D.; März, W.; Mirrakhimov, E.; Miserez, A.R.; Mitchenko, O.; Nawawi, H.; Nilsson, L.; Nordestgaard, B.G.; Paragh, G.; Petrulioniene, Z.; Pojskic, B.; Reiner, Ž.; Sahebkar, A.; Santos, L.E.; Schunkert, H.; Shehab, A.; Slimane, M.N.; Stoll, M.; Su, T.C.; Susekov, A.; Tilney, M.; Tomlinson, B.; Tselepis, A.D.; Vohnout, B.; Widén, E.; Yamashita, S.; Catapano, A.L.; Ray, K.K. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. Atheroscler. Suppl., 2016, 22, 1-32.
[http://dx.doi.org/10.1016/j.atherosclerosissup.2016.10.001] [PMID: 27939304]
[100]
Khera, A.V.; Won, H.H.; Peloso, G.M.; Lawson, K.S.; Bartz, T.M.; Deng, X.; van Leeuwen, E.M.; Natarajan, P.; Emdin, C.A.; Bick, A.G.; Morrison, A.C.; Brody, J.A.; Gupta, N.; Nomura, A.; Kessler, T.; Duga, S.; Bis, J.C.; van Duijn, C.M.; Cupples, L.A.; Psaty, B.; Rader, D.J.; Danesh, J.; Schunkert, H.; McPherson, R.; Farrall, M.; Watkins, H.; Lander, E.; Wilson, J.G.; Correa, A.; Boerwinkle, E.; Merlini, P.A.; Ardissino, D.; Saleheen, D.; Gabriel, S.; Kathiresan, S. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J. Am. Coll. Cardiol., 2016, 67(22), 2578-2589.
[http://dx.doi.org/10.1016/j.jacc.2016.03.520] [PMID: 27050191]
[101]
Ito, M.K.; Watts, G.F. Challenges in the diagnosis and treatment of homozygous familial hypercholesterolemia. Drugs, 2015, 75(15), 1715-1724.
[http://dx.doi.org/10.1007/s40265-015-0466-y] [PMID: 26370207]
[102]
Gagné, C.; Gaudet, D.; Bruckert, E. Efficacy and safety of ezetimibeco administered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation, 2002, 105(21), 2469-24.
[103]
Maxfield, F.R.; Tabas, I. Role of cholesterol and lipid organization in disease. Nature, 2005, 438(7068), 612-621.
[http://dx.doi.org/10.1038/nature04399] [PMID: 16319881]
[104]
Gille, A.; Bodor, E.T.; Ahmed, K.; Offermanns, S. Nicotinic acid: pharmacological effects and mechanisms of action. Annu. Rev. Pharmacol. Toxicol., 2008, 48, 79-106.
[http://dx.doi.org/10.1146/annurev.pharmtox.48.113006.094746] [PMID: 17705685]
[105]
Chang, Y.; Robidoux, J. Dyslipidemia management update. Curr. Opin. Pharmacol., 2017, 33, 47-55.
[http://dx.doi.org/10.1016/j.coph.2017.04.005] [PMID: 28527325]
[106]
Scaldaferri, F.; Pizzoferrato, M.; Ponziani, F.R.; Gasbarrini, G.; Gasbarrini, A. Use and indications of cholestyramine and bile acid sequestrants. Intern. Emerg. Med., 2013, 8(3), 205-210.
[http://dx.doi.org/10.1007/s11739-011-0653-0] [PMID: 21739227]
[107]
Davidson, M.H.A. A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia. J. Clin. Lipidol., 2011, 5(2), 76-81.
[http://dx.doi.org/10.1016/j.jacl.2011.01.005] [PMID: 21392720]
[108]
Altmann, S.W.; Davis, H.R., Jr; Zhu, L.J.; Yao, X.; Hoos, L.M.; Tetzloff, G.; Iyer, S.P.; Maguire, M.; Golovko, A.; Zeng, M.; Wang, L.; Murgolo, N.; Graziano, M.P. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science, 2004, 303(5661), 1201-1204.
[http://dx.doi.org/10.1126/science.1093131] [PMID: 14976318]
[109]
Temel, R.E.; Rudel, L.L. Diet effects on atherosclerosis in mice. Curr. Drug Targets, 2007, 8(11), 1150-1160.
[http://dx.doi.org/10.2174/138945007782403847] [PMID: 18045093]
[110]
Rosenson, R.S.; Hegele, R.A.; Fazio, S.; Cannon, C.P. The evolving future of PCSK9 inhibitors. J. Am. Coll. Cardiol., 2018, 72(3), 314-329.
[http://dx.doi.org/10.1016/j.jacc.2018.04.054] [PMID: 30012326]
[111]
Robinson, J.G.; Huijgen, R.; Ray, K.; Persons, J.; Kastelein, J.J.; Pencina, M.J. Determining when to add nonstatin therapy. J. Am. Coll. Cardiol., 2016, 68(22), 2412-2421.
[http://dx.doi.org/10.1016/j.jacc.2016.09.928] [PMID: 27908345]
[112]
Raal, F.J.; Hovingh, G.K.; Catapano, A.L. Familial hypercholesterolemia treatments: Guidelines and new therapies. Atherosclerosis, 2018, 277, 483-492.
[http://dx.doi.org/10.1016/j.atherosclerosis.2018.06.859] [PMID: 30270089]
[113]
Santos, R.D.; Duell, P.B.; East, C.; Guyton, J.R.; Moriarty, P.M.; Chin, W.; Mittleman, R.S. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur. Heart J., 2015, 36(9), 566-575.
[http://dx.doi.org/10.1093/eurheartj/eht549] [PMID: 24366918]
[114]
Thompson, G.R.; Catapano, A.; Saheb, S.; Atassi-Dumont, M.; Barbir, M.; Eriksson, M.; Paulweber, B.; Sijbrands, E.; Stalenhoef, A.F.; Parhofer, K.G. Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Curr. Opin. Lipidol., 2010, 21(6), 492-498.
[http://dx.doi.org/10.1097/MOL.0b013e3283402f53] [PMID: 20935563]
[115]
Julius, U. Current role of lipoprotein apheresis in the treatment of high-risk patients. J. Cardiovasc. Dev. Dis., 2018, 5(2), 27.
[http://dx.doi.org/10.3390/jcdd5020027] [PMID: 29747383]
[116]
Raal, F.J. Orion-9 Inclisiran for heterozygous familial hypercholesterolemia. American Heart Association Annual Scientific Sessions (AHA 2019), Philadelphia, PA2019.
[117]
Watts, G.F. RNA interference targeting hepatic angiopoietin-like protein 3 results in prolonged reduction in plasma triglycerides and LDL-C in human subjects. American Heart Association Annual Scientific Sessions (AHA 2019), Philadelphia PA2019.
[118]
ClinicalTrials.gov. A gene therapy study for homozygous Familiar hypercholesterolemia. https://clinicaltrials.gov/ct2/show/NCT02651675
[119]
Centers for Diseases Control and Prevention. Genomics & precisión health. Tier 1 genomic applications and their importance to public health, https://www.cdc.gov/genomics/implementation/toolkit/tier1.htm

Rights & Permissions Print Cite
Article Metrics
32
1
© 2024 Bentham Science Publishers | Privacy Policy